Improving the Care of Patients Living with Metastatic Breast Cancer RFP

Well-being, Health and Biomedical Discovery

Deadlines

Academic Unit: inquire with unit

Memorial Deadline: Thursday 14th, March 2024

External Deadline: Thursday 21st, March 2024


Description

Rethink Breast Cancer (Rethink) is known for making positive change and rethinking the status quo when it comes to breast cancer. Rethink educates, empowers and advocates for system changes to improve the experience and outcomes of those with breast cancer, focusing on historically underserved groups: people diagnosed at a younger age, those with metastatic breast cancer (mBC) and people systemically marginalized due to race, income or other factors. Through collaboration, Rethink keeps the community’s voice firmly at the centre and drives impact in ways that matter most.

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. Beyond treatments, Pfizer works hand-in-hand with the broader cancer community to best support people living with cancer. In this spirit, Pfizer is very proud to partner with Rethink Breast Cancer to launch this request for proposal program aimed at helping improve the lives and care of people living with breast cancer.

Specific Area of Interest: The intent of this RFP is to encourage proposals for the implementation of strategies that will measurably improve the quality of care of persons with mBC. Projects should use optimal measures to improve care for persons with mBC, where treatment goals focus on improving quality and length of life as there is, to date, no known cure. We welcome a diversity of projects that will improve the outcomes of persons with metastatic breast cancer including pilot projects that could lead to larger efforts that could potentially impact clinical care. Well thought out and tested modifications allow for more efficient and effective patient care.

Providing appropriate resources and education to people with mBC, their caregivers, and family members is crucial to help ensure they are informed and can participate in the shared clinical decision-making process. While the digital delivery of care can provide persons with mBC with flexibility and health care providers with further reach, submissions that underscore the importance of person-to-person care are also appreciated.

Refer to complete details in the full RFP document. If you have questions regarding this RFP, please direct them in writing to Jacqueline Waldrop, Grant Officer (jacqueline.waldrop@pfizer.com).

Date RFP Issued: January 22, 2024

Geographic Scope: Canada

Clinical Area: Oncology – metastatic breast cancer

Link to full RFP: Improving the Care of Patients Living with Metastatic Breast Cancer

Application Due Date: March 21, 2024; 11:59 pm EST


Funding Sources

Pfizer Inc



This opportunity was posted by: RGCS

Last modified: January 24, 2024